China Universal Asset Management Co. Ltd. Has $20.18 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

China Universal Asset Management Co. Ltd. boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 218,445 shares of the biopharmaceutical company’s stock after purchasing an additional 1,834 shares during the quarter. Gilead Sciences accounts for approximately 1.9% of China Universal Asset Management Co. Ltd.’s holdings, making the stock its 9th biggest position. China Universal Asset Management Co. Ltd.’s holdings in Gilead Sciences were worth $20,178,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. nVerses Capital LLC acquired a new position in shares of Gilead Sciences in the third quarter valued at $25,000. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $29,000. Valued Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares during the period. Crews Bank & Trust acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at about $31,000. Finally, Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences in the second quarter valued at about $33,000. 83.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on GILD. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a report on Wednesday, December 11th. Robert W. Baird boosted their price target on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Wells Fargo & Company increased their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Piper Sandler boosted their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Finally, Truist Financial increased their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $98.39.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the sale, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock worth $42,130,461 in the last three months. Insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $97.20 on Friday. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The company’s 50-day moving average is $92.42 and its two-hundred day moving average is $85.77. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a market cap of $121.14 billion, a PE ratio of 1,080.00, a PEG ratio of 1.34 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period in the prior year, the business posted $2.29 earnings per share. Gilead Sciences’s revenue was up 7.0% compared to the same quarter last year. Equities analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.